Sitaglomet Metformin Tablets 50/1000 mg
Sitagliptin Phosphate · Metformin Hydrochloride
Prescription medication · Combination
Aliko Pharmaceutical Co., Ltd.
MFDS item code 201507993 · Approved 2015.11.27
This product's status changed to Approval withdrawn on 2023.05.18. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used in conjunction with dietary and exercise therapy to help improve blood sugar control in patients with type 2 diabetes. Initially, it can be administered alone to patients who have no previous experience with diabetes medication. It may also be used if blood sugar control is inadequate with monotherapy using metformin or sitagliptin. Additionally, it can be used in combination with metformin and sulfonylurea, or metformin and thiazolidinedione therapy when adequate blood sugar control is not achieved. This drug can also be used effectively with insulin and metformin if control is still inadequate, providing various options for improving blood sugar control.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received drug treatment for diabetes and whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is one tablet of 50/500 mg twice daily. The dose may be increased to one tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with concomitant metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined taking the patient's blood glucose level and current dose into consideration. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have evaluated the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, use caution and ensure appropriate monitoring. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication is composed of two ingredients: sitagliptin and metformin, and is used for blood sugar control in patients with type 2 diabetes. Firstly, during the use of this medication, severe allergic reactions such as skin rash, swelling, or difficulty breathing may occur. If such symptoms arise, stop taking the medication immediately and consult a doctor. Also, acute pancreatitis, a serious inflammation of the pancreas, may occur, so if symptoms such as abdominal pain, vomiting, or fever appear, inform a healthcare professional immediately. The metformin in this drug can cause lactic acidosis, a rare but potentially fatal metabolic condition. Therefore, patients with impaired kidney function, liver dysfunction, severe infections, or dehydration should not take this medication. Specifically, if kidney function is moderately impaired or if there are acute conditions such as heart failure, acute myocardial infarction, or sepsis, this drug should not be used. Administration should also be suspended before and after examinations using iodinated contrast agents. This medication has not been confirmed safe for use in pregnant or breastfeeding women, nor in children and adolescents under 18 years of age. While taking this medication, regular kidney function tests should be conducted to monitor kidney status, and alcohol consumption should be avoided as it may increase the risk of lactic acidosis. The risk of hypoglycemia may increase when taken with other blood sugar-lowering medications, so patients should be cautious of hypoglycemic symptoms and may need adjustments in dosages of those medications as necessary. Additionally, irregular meals, vigorous exercise, and nutritional imbalances can increase the risk of hypoglycemia or lactic acidosis, so caution is advised. Severe joint pain, skin conditions, and liver dysfunction have been reported as side effects, so if any abnormal symptoms occur, inform a healthcare professional immediately. After surgery, the use of this medication should be suspended for a certain period, and it is important for patients and their families to receive adequate education regarding the medication's side effects and precautions.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air and kept at room temperature between 1 to 30 degrees Celsius. Proper storage can help maintain the efficacy of the medication for a longer period.
Red oval film-coated tablet
28 tablets (14 tablets/PTP × 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate · Metformin Hydrochloride
Prescription medication · Combination
Aliko Pharmaceutical Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.